- Price
- $43.25
- Day
- -1.59%
- Mkt Cap
- $2.11B
- 52W Range
- $15.86 – $50.81
- Volume
- 703.1K
- Beta
- 1.58
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Zoetis (NYSE: ZTS - Get Free Report) and Urogen Pharma (NASDAQ: URGN - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation. Profitability This table compares Zoetis and Urogen Pharma's net
Read full article
UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of Zusduri for recurrent non-muscle invasive bladder cancer. Zusduri achieved an 80% complete response rate in the ENVISION trial, with a 64.5% chance of remaining disease-free at 3 years among responders. URGN-103, a next-generation mitomycin-based product, is positioned to replace Zusduri, offering manufacturing and convenience advantages; NDA submission is complete and approval is likely.
Read full article
Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.
Read full article
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline.
Read full article
PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Read full article
BlackRock Inc. purchased a new position in Urogen Pharma (NASDAQ: URGN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,201,461 shares of the company's stock, valued at approximately $117,814,000. BlackRock Inc. owned 6.57% of Urogen Pharma at the end of
Read full article